The closing price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was $0.37 for the day, up 0.35% from the previous closing price of $0.37. In other words, the price has increased by $+0.0013 from its previous closing price. On the day, 681087 shares were traded.
Ratios:
Our analysis of TNXP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.77. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 21.95M and an Enterprise Value of 16.18M. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.59 while its Price-to-Book (P/B) ratio in mrq is 0.06. Its current Enterprise Value per Revenue stands at 4.06 whereas that against EBITDA is -0.13.
Stock Price History:
Over the past 52 weeks, TNXP has reached a high of $4.50, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 0.3434, while the 200-Day Moving Average is calculated to be 0.8332.
Shares Statistics:
TNXP traded an average of 1.79M shares per day over the past three months and 1.33M shares per day over the past ten days. A total of 80.82M shares are outstanding, with a floating share count of 80.81M. Insiders hold about 0.01% of the company’s shares, while institutions hold 20.77% stake in the company. Shares short for TNXP as of Feb 15, 2024 were 596.5k with a Short Ratio of 0.33, compared to 275.01k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.02% and a Short% of Float of 1.02%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$1.64 for the current quarter, with a high estimate of -$1.46 and a low estimate of -$1.83, while EPS last year was -$3.5. The consensus estimate for the next quarter is -$1.35, with high estimates of -$1.35 and low estimates of -$1.35.
Analysts are recommending an EPS of between -$4.49 and -$8.8 for the fiscal current year, implying an average EPS of -$6.64. EPS for the following year is -$3.14, with 3 analysts recommending between -$0.91 and -$5.83.
